INmune Bio Inc. (INMB)
Nasdaq · Healthcare · Biotechnology
$1.94+0.52%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $53.8M
- 52-week range
- $1.09 – $2.60
- 52-week change
- −6.31%
- EPS (trailing)
- −$0.67
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $50K (+257.14%)
- Net income
- −$46.0M
- Operating margin
- −94766.0%
- Diluted EPS
- −$1.86
- Free cash flow
- −$23.6M
From the company’s annual report on SEC EDGAR.
About INmune Bio Inc.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Headquarters: Boca Raton, United States · 21 employees · inmunebio.com